Dalrada Technology Group, Inc. filings document the company's public-company reporting, corporate name history, material events, financing arrangements, and subsidiary obligations. Recent Form 8-K disclosures address shareholder communications, credit and security agreements involving Genefic Inc., amendments to previously reported financial-obligation disclosures, and notices of default under loan, guaranty, security, warrant, and factoring arrangements.
The filing record also includes Form 12b-25 notifications for quarterly-report timing and disclosures tied to auditor review. These documents frame Dalrada's formal reporting around its clean energy, atmospheric water generator, and semiconductor deposition markets, while also recording capital-structure, reporting-status, risk, and obligation-related matters.
Dalrada Technology Group, Inc. (DHTI) paid IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC a $20,000 lump-sum settlement on October 2, 2026, when the settlement closed. Genefic, Inc., Dalrada’s wholly owned subsidiary, and certain affiliates and subsidiaries were also parties. IBS had provided no funding under the financing documents; in September 2026, it asserted events of default and demanded approximately $1,162,246, which Dalrada disputed.
At closing, the financing documents terminated and related obligations were discharged; the secured promissory note and pre-funded warrant were cancelled. Dalrada’s corporate guaranty, Brian Bonar’s personal guaranty, and IBS’s liens, security interests and account-control rights were released. IBS withdrew its notices and asserted enforcement steps. Mutual releases cover claims relating to the financing documents and notices, subject to stated exclusions; each party bears its own attorneys’ fees and expenses.
On October 5, 2026, IBS confirmed receipt of the settlement, withdrawal of the notices, termination of the financing documents and release of security interests. A termination statement was filed with the Wyoming Secretary of State. Dalrada stated that no amounts remained owing to IBS and no IBS indebtedness, guaranty, lien or equity right remained outstanding. The agreement provides for mutual non-admission and does not constitute an admission of default, liability or wrongdoing.
Dalrada Technology Group, Inc. (DHTI) reports that its wholly owned subsidiary Genefic, Inc. and related affiliates entered into a $20,000,000 Master Performance Standby Letter of Credit and Guaranty Agreement and a $5,000,000 Master Credit, Security, and Account Purchase Agreement with IBS entities effective December 31, 2025, but received no funding under these facilities.
After Genefic elected to terminate the financing relationship, IBS declared Events of Default, accelerated a secured promissory note, and demanded various fees and charges, asserting a total of $1,162,246 (exclusive of interest and additional costs) plus additional qualifying collateral of not less than $875,000. IBS has also reserved extensive remedies, including potential control over deposit accounts, receivables, and pledged equity interests, and has issued default notices to Dalrada as corporate guarantor and to Brian Bonar as personal guarantor.
Dalrada disputes the asserted Events of Default, the demanded amounts, and the early termination fees, emphasizing that no funding was ever provided under the agreements. The company believes it has meritorious defenses and intends to vigorously contest IBS’s claims, while cautioning that if IBS were to prevail or exercise its reserved remedies, this could have a material adverse effect on Dalrada’s liquidity, financial condition, results of operations, and on Genefic’s operations, and could trigger defaults under other indebtedness.
Dalrada Technology Group, Inc. reported weak results for the quarter ended March 31, 2026, with total revenue of $2.6M, down from $4.6M in the prior-year quarter. Gross profit was $0.8M, while operating expenses of $4.1M drove a loss from operations of $3.3M.
Net loss attributable to stockholders was $4.3M for the quarter and $14.8M for the nine months, compared with $4.2M and $17.7M a year earlier. The company ended March 31, 2026 with cash and cash equivalents of $0.4M, total liabilities of $38.5M, and a stockholders’ deficit of $20.8M. Dalrada discloses negative working capital of $22.0M and states that recurring losses, cash burn, and reliance on debt and equity financing raise substantial doubt about its ability to continue as a going concern.
Dalrada Technology Group, Inc. submitted a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026. The company says additional time is needed to compile and analyze information, complete financial statements and disclosures, and allow review by its independent registered public accounting firm. Dalrada expects to file the Form 10-Q as soon as practicable and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25.
Dalrada Technology Group, Inc. reported that it and certain subsidiaries received a notice of default on multiple credit facilities from Nautilus entities on April 24, 2026. The lender cites missed required payments and is demanding a $500,000 cure payment by May 1, 2026.
If the cure is not made, the lender may accelerate the loan balances and begin enforcement actions under the term loan and factoring agreements. Dalrada is reviewing the notice and plans to discuss potential resolutions, but states there is no assurance the defaults will be cured or that acceleration and enforcement will be avoided.
Dalrada Technology Group reported continued losses and severe balance sheet weakness for the quarter ended December 31, 2025. Total revenue was $3.26 million, roughly flat versus the prior year’s $3.11 million, while six‑month revenue fell to $7.36 million from $9.15 million. Gross profit improved to $1.12 million in the quarter, but selling, general and administrative expenses of $4.70 million kept operations unprofitable, leading to a quarterly operating loss of $3.57 million and a six‑month net loss of $10.49 million.
The company’s financial position is strained. It ended the period with only $70,074 of cash and cash equivalents, total assets of $17.59 million, and total liabilities of $34.49 million, resulting in a stockholders’ deficit of $16.90 million. Management discloses negative working capital of $15.34 million and states there is “substantial doubt” about Dalrada’s ability to continue as a going concern without new financing and improved subsidiary performance.
Dalrada relies heavily on related‑party financing, with $8.58 million in related‑party payables and $4.64 million in related‑party notes payable, and has layered on multiple high‑cost loans and revenue purchase agreements. Operating cash outflows of $3.26 million in the first half of fiscal 2026 were covered only by $3.00 million of net cash from financing activities.
Dalrada Technology Group, Inc. filed a notification that it will be late submitting its quarterly report on Form 10-Q for the period ended December 31, 2025. The company states the filing delay is because it is in the final review process with its auditors and indicates the report will be filed within the standard grace period allowed. Dalrada also reports that all other required periodic reports over the past 12 months have been filed and that it does not anticipate any significant change in results of operations compared with the same period last year.
Dalrada Technology Group, through its subsidiary Genefic Inc., amended a prior report to clarify that new financing agreements create up to $25,000,000 in aggregate commitments, not $20,000,000 as first disclosed. The package combines up to $20,000,000 of standby letters of credit and related guarantees with a linked $5,000,000 revolving accounts receivable facility supporting Genefic’s healthcare operations.
The facilities run from December 31, 2025 to December 31, 2030 and are secured by first-priority liens on substantially all assets of Genefic and the parent company, plus a pledge of 100% of equity in all subsidiaries. Chairman and CEO Brian Bonar has provided an unlimited personal guaranty that is joint and several with the company’s obligations, and the board highlights resulting conflicts of interest between his personal exposure and his duties to shareholders. Upfront consideration includes $140,000 in cash, a $165,000 promissory note, and a pre-funded warrant valued at $225,000.
Dalrada Technology Group, through its wholly owned subsidiary Genefic Inc., entered into a financing structure providing up to $20,000,000 in guarantees and related credit support with IBS-affiliated funds. A related receivables-based revolving facility may provide up to $5,000,000 in funding for Genefic’s healthcare operations.
The arrangements are secured by first-priority liens on substantially all assets of Genefic and a first-priority security interest in substantially all assets of Dalrada, plus a pledge of 100% of the equity in all Dalrada subsidiaries. CEO Brian Bonar also provided an unlimited personal guaranty of Genefic’s obligations, which the Board identified as creating multiple potential conflicts of interest. Dalrada did not receive separate consideration for its upstream guarantee beyond benefits to Genefic.
Dalrada Technology Group, Inc. filed a current report to share that its Chief Executive Officer and Chairman, Brian Bonar, issued an open letter to shareholders dated January 20, 2026. The letter reviews the company’s 2025 performance, discusses operational progress in its core markets of renewable energy and heat pumps, atmospheric water generators, and semiconductor deposition solutions, and highlights recent partnerships, installations, and restructuring efforts. It also outlines Dalrada’s strategic focus and outlook for 2026 and beyond. The letter is included as Exhibit 99.1 and is furnished, rather than filed, under the securities laws.